Table 1.

Summary of recommendations from the Willemse group review on patient suitability for AS

Domain	Current EAU 2020 guidelines	Willemse et al 2022 Recommendations	Strength of evidence
Inclusion criteria	mpMRI prior to biopsy	Low volume International Society of Urological Pathology (ISUP) Grade 2 disease with 2-3 positive cores and <50% cancer involvement per core (Favorable)	Weak
	ISUP 1 disease only	ISUP 2 with >3 cores positive should be excluded	Weak
Surveillance	PSA every 6 months	Confirmatory biopsy within the first 2 years	Weak
	DRE every 6 months	Surveillance biopsy at least every 3 years for 10 years	Weak
	No need for confirmatory biopsy if mpMRI done prior to diagnostic biopsy	If mpMRI is not available repeat biopsy	Weak
	mpMRI prior to all surveillance biopsy	Any increase in core involvement at repeat biopsy should be reclassified	Weak

mpMRI, multiparametric magnetic resonance imaging; DRE, digital rectal examination.